These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Patel AB; O'Hare T; Deininger MW Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390 [TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463 [TBL] [Abstract][Full Text] [Related]
6. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1. Feng H; Fu Y; Cui Z; Zhou M; Zhang L; Gao Z; Ma S; Chen C Br J Haematol; 2023 Sep; 202(6):1178-1191. PubMed ID: 37469124 [TBL] [Abstract][Full Text] [Related]
7. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693 [TBL] [Abstract][Full Text] [Related]
8. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755 [TBL] [Abstract][Full Text] [Related]
9. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1 Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618 [TBL] [Abstract][Full Text] [Related]
10. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283 [TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Kaehler M; Cascorbi I Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601 [TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study. Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202 [TBL] [Abstract][Full Text] [Related]
13. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing. Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391 [TBL] [Abstract][Full Text] [Related]